Paper Agent · Alzheimer’s disease and related dementias
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
Chad J Swanson; Yong Zhang; Shobha Dhadda; Jinping Wang; June Kaplow; Robert Y K Lai; Lars Lannfelt; Heather Bradley; Martin Rabe; Akihiko Koyama; Larisa Reyderman; Donald A Berry; Scott Berry; Robert Gordon; Lynn D Kramer; Jeffrey L Cummings
Originally published in Alzheimer's research & therapy · 2021-04-17
